Blueprint Medicines Reports Fourth Quarter and Full Year 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
Blueprint Medicines (BPMC) Misses Q4 EPS by 5c
March 11, 2016 8:10 AM ESTBlueprint Medicines (NASDAQ: BPMC) reported Q4 EPS of ($0.58), $0.05 worse than the analyst estimate of ($0.53). Revenue for the quarter came in at $4.64 million versus the consensus estimate of $2.85 million.
As of December 31, 2015, cash and cash equivalents were $162.7 million, as compared to $47.2 million as of... More
